Health authorities and pharmaceutical companies are planning to test several new vaccines to prevent Ebola infection over the next few months, including one that is taken as a tablet, making it easier to deploy in West Africa.
The
plans signify that a response to the Ebola outbreak is finally
gathering steam. It is still unclear if any of these vaccines will work,
however, and even if they do, they may not be ready in time to help
stem the current epidemic.
Starting
in January, two vaccines will be tested in large studies in the West
African countries most affected by the outbreak, the World Health Organization
said on Tuesday. At least three other vaccines will begin safety
testing in healthy volunteers outside the outbreak zone in the first
quarter of 2015.
One
of those three is actually a combination of two inoculations being
developed by Johnson & Johnson and Bavarian Nordic, a Danish
company.
Johnson & Johnson announced early Wednesday that it was committing
$200 million to the program, including making an equity investment of
about $43 million in Bavarian Nordic to help pay for that company’s part
in the project. It says it plans to begin safety trials in January and
hopes to produce one million doses in 2015, with 250,000 available for
broad application in clinical trials by May.
“Typically,
you don’t make hundreds of thousands of vaccines before you know what
the safety and immunogenicity is,” said Dr. Paul Stoffels, chief
scientific officer of Johnson & Johnson. “This time, we will do
that.”
The
two most advanced vaccines in terms of development is each undergoing
testing in about 250 healthy adult volunteers in the United States and
other countries outside the outbreak region.
One of the vaccines was developed by the National Institutes of Health and GlaxoSmithKline. The other was initially developed by the Public Health Agency of Canada and licensed to NewLink Genetics, a company in Iowa.
The studies, known as Phase 1 clinical trials, are determining if the vaccines are safe and generate an immune response.
Preliminary results are expected by the end of the year, Marie-Paule
Kieny, the World Health Organization’s assistant director general for
health systems and innovation, said in a news conference in Geneva on
Tuesday.
But
she said her organization was not waiting for those results. It is
already planning the next stage of testing, to be ready to start in
January if the vaccines pass the initial tests. Those new trials will
take place in the affected countries in West Africa and would involve
tens of thousands of doses, she said.
No comments:
Post a Comment